Patents Examined by Irina Neagu
  • Antimicrobial compositions containing cationic active ingredients
    Patent number: 11590065
    Abstract: The antimicrobial composition of the present invention comprises a cationic active ingredient, a foam boosting surfactant, a foam boosting copolymer, a foam stabilizer, and a chelating agent. The present antimicrobial compositions are free of the antimicrobial agent triclosan (i.e., 2,4,4?-trichloro-2?hydroxy-diphenylether), have rapid cidal activity, provide stable copious foam and exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: February 28, 2023
    Assignee: ECOLAB USA INC.
    Inventors: Daniel E. Pedersen, Carter M. Silvernail, Kerrie E. Walters, Hilina Emiru
  • Isoflavonoid compounds and methods for the treatment of cancer
    Patent number: 11583514
    Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: February 21, 2023
    Assignee: MEI Pharma, Inc.
    Inventors: George Jeoffreys, Alison Johnson, Andrew Heaton, Ofir Moreno
  • Compositions and methods for the treatment of brain injury
    Patent number: 11576885
    Abstract: Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: February 14, 2023
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventor: Akiva S. Cohen
  • Bupropion as a modulator of drug activity
    Patent number: 11524008
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: December 13, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Method of providing celiprolol therapy to a patient
    Patent number: 11523997
    Abstract: The present disclosure relates to the field of treatment of an orphan disease, in particular treatment of vascular Ehlers-Danlos syndrome (vEDS). More specifically, the present disclosure relates to novel up-titration dosage regimens (e.g., escalating dosage regimens) effective for treating vEDS patients with celiprolol.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: December 13, 2022
    Assignee: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Inventor: Michael Frank
  • Compounds and methods for treating nematode infections
    Patent number: 11517568
    Abstract: The present application relates to the treatment of nematode infections.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: December 6, 2022
    Assignee: The Governing Council of The University of Toronto
    Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Andrew Burns, Rachel Ross, Mark Lautens
  • Pharmaceutical composition comprising pomalidomide
    Patent number: 11517536
    Abstract: The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: December 6, 2022
    Assignee: Synthon B.V.
    Inventors: Sonia Garcia Jimenez, Luis Nogueiras Nieto, Lisardo Alvarez Fernandez, Jose Velada Calzada
  • Use of metformin salt in the treatment of cerebral infarction
    Patent number: 11497722
    Abstract: The present invention provides the use of a metformin salt, particularly metformin monothreonate, in the preparation of a medicament for treating cerebral infarction. The metaformin monothreonate of the present invention has an excellent effect in the treatment of cerebral infarction. The present invention also provides a method for preparing metformin monothreonate and a composition comprising metformin monothreonate.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 15, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Xuechu Zhen, Zongyin Liu, Linyi Qian, Huimin Cao
  • Methods of treating fragile X mental retardation syndrome
    Patent number: 11491144
    Abstract: The invention provides a method of treating FX syndrome and FX premutation by administering an effective amount of a ?-opioid receptor antagonist to an individual having FX syndrome or FX premutation.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 8, 2022
    Assignees: The Florida State University Research Foundation, Incorporated, Avekshan LLC
    Inventors: Pradeep G. Bhide, Deirdre McCarthy, Enrique Carrazana, John W. Cran
  • Anthranilic amides and the use thereof
    Patent number: 11465978
    Abstract: Disclosed are anthranilic amide derivatives having the formula. Compositions are disclosed that include the anthranilic amide derivatives and the use of the anthranilic amide derivatives for the manufacture of a medicament. Further disclosed are methods of inhibiting or treating cancer, inhibiting or reversing an epithelial to mesenchymal cellular transition, and/or inhibiting MEK1/2 and/or MEK 5 enzymatic activity in a subject by administering to the subject an effective amount of a disclosed anthranilic amide derivative.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: October 11, 2022
    Assignees: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND, DUQUESNE UNIVERSITY OF THE HOLY GHOST
    Inventors: Suravi Chakrabarty, Patrick T. Flaherty, Darlene Monlish, Jane E. Cavanaugh, Matthew E. Burow, Steven Elliott, Van T. Hoang
  • Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
    Patent number: 11426368
    Abstract: Provided herein are plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The disclosure includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: August 30, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, EASTERN MICHIGAN UNIVERSITY
    Inventors: Daniel A. Lawrence, Cory Emal, Ashley Reinke, Shih-Hon Li
  • Use of metformin and sodium butyrate for treating conditions induced by chronic inflammation
    Patent number: 11382878
    Abstract: Disclosed herein are compositions and methods for the treatment of conditions induced by chronic inflammation. According to some embodiments, the compositions and methods involve the use of metformin and sodium butyrate in the treatment of conditions induced by chronic inflammation.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: July 12, 2022
    Assignee: JOHNPRO BIOTECH INC.
    Inventors: Kwan-Hwa Chi, Yu-Shan Wang, Hsin-Chien Chiang, Kai-Chung Cheng
  • Compositions and methods for increasing efficiency of cardiac metabolism
    Patent number: 11376330
    Abstract: Compositions and methods for increasing efficiency of cardiac metabolism are provided.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: July 5, 2022
    Assignee: IMBRIA PHARMACEUTICALS, INC.
    Inventor: Andrew D. Levin
  • Compounds and methods for treating nematode infections
    Patent number: 11364234
    Abstract: The present application relates to the treatment of nematode infections.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: June 21, 2022
    Assignees: The Governing Council of the University of Toronto, Ontario Institute for Cancer Research (OICR)
    Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Daniel Kulke, Genna M. Luciani, Andrew Burns, Mark Lautens, Rachel Ross, David Uehling
  • Fused cyclooctyne compounds and their use in metal-free click reactions
    Patent number: 11358921
    Abstract: The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: June 14, 2022
    Assignee: SYNAFFIX B.V.
    Inventors: Floris Louis Van Delft, Floris Petrus Johannes Theodorus Rutjes, Frederik Jan Dommerholt
  • Bupropion as a modulator of drug activity
    Patent number: 11344544
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: May 31, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Use of isothiocyanate functional surfactants as NRF2 inducers to treat epidermolysis bullosa simplex and related diseases
    Patent number: 11339125
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers and/or activity modifiers.
    Type: Grant
    Filed: May 5, 2020
    Date of Patent: May 24, 2022
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • TXNIP-TRX complex inhibitors and methods of using the same
    Patent number: 11324731
    Abstract: Disclosed herein, inter alia, are compounds and methods for inhibiting the thioredoxin-thioredoxin-interacting-protein (TXNIP-TRX) complex.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: May 10, 2022
    Assignee: CITY OF HOPE
    Inventors: Rama Natarajan, Feng Miao, Nagarajan Vaidehi, Supriyo Bhattacharya, Adrien Beau Larsen
  • Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
    Patent number: 11312718
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: April 26, 2022
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
  • Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
    Patent number: 11306057
    Abstract: The present invention relates to methods, formulations, and compositions for the treatment of biofilms. In particular, the application discloses isothiocyanate functional surfactants either alone or combination with adjunct agents to treat biofilms.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: April 19, 2022
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver